No Data
No Data
BioMarin Pharmaceutical Sues Ascendis Pharma for Patent Infringement in Germany
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading
Evercore ISI Remains a Buy on Ascendis Pharma (ASND)
Wells Fargo Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $289
This Coca-Cola Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Ascendis Pharma Initiated at Buy by UBS